20
Participants
Start Date
October 30, 2019
Primary Completion Date
May 30, 2021
Study Completion Date
October 31, 2021
Oxybutynin, Solifenacin, Tolterodine, Trospium, or Fesoterodine
Study participants will be evaluated for urgency urinary incontinence and will be offered treatment with a standard of care anticholinergic medication for 6 weeks. All study participants will fill out the UDI-6 and two day bladder diary at baseline before starting anticholinergic medication treatment. Participants will then provide a urine sample and blood draw to be assessed for urinary microbiome and inflammation. Anticholinergic medication will be taken daily for 6 weeks and the same procedures (UDI-6 questionnaire, bladder diary, urine sample except the blood draw for assessment) will be performed at the 6-week time period.
Brigham & Women's Hospital, Boston
Medical University of Silesia
OTHER
Brigham and Women's Hospital
OTHER